Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only treatment indicated for EoE in the U.S. for this age group TARRYTOWN, N.Y. and PARIS, June 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine (NEJM) has published results from a positive Phase 3 trial for Dupixent® (dupilumab ...

Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one yearDupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group Paris and Tarrytown, NY, June 26, 2024. The New England Journal of Medicine has published results from a positive phase 3 study o ...

Loading...Loading...Regeneron Pharmaceuticals Inc REGN released multiple ascending dose (MAD) data from a Phase 1 study evaluating garetosmab (anti-activin A) and trevogrumab (anti-myostatin) on body composition in healthy volunteers (n=34) at the American Diabetes Association meeting.The data demonstrated that combination therapy led to greater-than-additive increases in lean mass while decreasing fat mass in healthy participants.Thigh muscle volume (TMV) increased from baseline 7.7% with trevogrumab 6 mg/ ...

Biotech giant Regeneron Pharmaceuticals (REGN) is one of the few top biotech companies that has outperformed the industry year to date.Shares of the company have risen 19% year to date against the industry’s decline of 6.4%. Image Source: Zacks Investment ResearchRegeneron’s efforts to diversify its portfolio have impressed its investors, even as lead drug Eylea faces challenges. Regeneron’s top line is being boosted by its share of profits/losses in connection with the global sales of Dupixent. Partner San ...

At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ...

Loading...Loading...RBC Capital Markets analyst Brian Abrahams reiterated an Outperform rating on Regeneron Pharmaceuticals, Inc. REGN, raising the price forecast to $1,299 from $1,200.Abrahams surveyed 31 pulmonologist physicians who see high volumes of COPD patients.The analyst writes that the surveyed pulmonologists were excited about the ph.III data, the proportion of patients they view as having type 2 inflammation, and the expected rapidity of adoption post-approval all suggest dupixent’s COPD sales p ...

Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced that the FDA has approved a label expansion of the arthritis drug Kevzara (sarilumab).The drug is now approved in the United States for the treatment of patients weighing 63 kilograms or more with active polyarticular juvenile idiopathic arthritis (pJIA).The FDA approval is supported by evidence from adequate and well-controlled studies and pharmacokinetic data from adults with rheumatoid arthritis as well as a pharmacokinetic, pharma ...

会议主要讨论的核心内容 - 公司的资本配置策略包括三个支柱:首先是投资内部研发能力[5][6]，其次是投资制造能力[5]，第三是通过业务发展团队寻找补充性技术[6] - 公司预计到2026年底将偿还完毕与Sanofi的开发费用余额,这将为公司带来约6-8亿美元的额外利润[9][10] - EYLEA HD自获得永久J码后,处方量有所增加,新增处方医生也在不断增加,公司正在采取措施加快患者从其他药物转换到EYLEA HD[12][13][14][15][20][21] - 公司正在积极维护EYLEA 2mg剂量的知识产权,并采取措施防止竞争对手的仿制药上市[23][24][25][26][27] - 公司正在等待FDA对Dupixent用于COPD适应症的审批决定,对于获批持乐观态度[29][30][31] - 公司正在积极推进管线产品的临床试验,包括肥胖、过敏、肿瘤等多个领域,未来将有大量临床数据陆续公布[35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][58][59][60] - 公司正在利用自身的技术优势,如VelociSuite小鼠模型,优化生物特异性抗体的开发[64][65] - 公司对linvoseltamab的上市前景充满信心,认为其在疗效、安全性和用药便利性等方面都有优势[67][68][69][70] - 公司目前现金充裕,未来可能会考虑并购或派发股息,但目前还没有具体计划[74][75][76][77][78] 问答环节重要的提问和回答 问题1 **Salveen Richter 提问** 公司如何看待linvoseltamab的上市前景[66] **Chris Fenimore 回答** linvoseltamab在疗效、安全性和用药便利性等方面都有优势,公司对其上市前景充满信心[67][68][69][70] 问题2 **Salveen Richter 提问** 公司如何看待其管线产品的临床进展[34] **Chris Fenimore 回答** 公司正在积极推进多个领域的管线产品,未来将有大量临床数据陆续公布[35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][58][59][60] 问题3 **Salveen Richter 提问** 公司如何看待资本配置策略[2] **Chris Fenimore 回答** 公司的资本配置策略包括三个支柱:首先是投资内部研发能力,其次是投资制造能力,第三是通过业务发展团队寻找补充性技术[5][6]

Approval in patients with pJIA weighing 63kg or greater adds to Kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica TARRYTOWN, N.Y. and CAMBRIDGE, MA, June 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for the treatment of patients weighing 63 kg or greater with active polyarticul ...

Approval in patients with pJIA weighing 63kg or greater adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica TARRYTOWN, N.Y. and CAMBRIDGE, MA, June 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for the treatment of patients weighing 63 kg or greater with active polyarticu ...